You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
复宏汉霖(02696.HK)就针对人体TROP2靶点抗体与CHIOME订独家许可协议
阿思达克 01-14 17:09
复宏汉霖(02696.HK)公布,公司於今日(14日)与Chiome订立独家许可协议,同意就针对人体TROP2靶点的抗体及相关的Chiome知识产权向公司授出独家权利及许可,并於中国所有人体疾病治疗及诊断应用领域内,就许可产品的研究、开发、生产及商业化授出独家权利。公司将向Chiome支付首付款100万美元(下同),开发里程碑款项合计不超过2,300万元,商业里程碑款项合计不超过8,650万元及年度净销售额的8%到10%计的特许权使用费。

许可产品是针对人体TROP2靶点的创新单克隆抗体,目前仍处於临床前研究阶段,具有开发抗体偶联药物、双特异性抗体、与多种抗体联合治疗的潜力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account